Topline results from the VALOR trial demonstrate the efficacy of a multivalent OspA vaccine candidate in preventing confirmed cases of Lyme disease.
The first human Lyme disease vaccine was 73% effective against the tick-borne illness, says Pfizer. They still plan to seek approval.
Just The News on MSN
Biden officials pushed COVID booster harder after surveillance found stroke increase: Sen. Johnson
Biden White House made edits to draft CDC and FDA "communications plan" to increase booster uptake, that "downplayed the significance of the safety signal" from "moderately" to "slightly" elevated, ...
After trials in Canada, drug company Pfizer announced it is applying for approvals to get U.S. approval to sell a Lyme disease vaccine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results